RE:RE:60 million cash and a promising lead drug
eunice12 wrote: Canaccord target just $3.25. You guys are dreaming this will bounce back or that volume means anything. Traders don't work at TTH. ELND005 is toast per Canaccord report I read, and venturestockpicks doesn't even realize it was the lead product, although he mixes tenses in a play on words which curiously makes him technically correct that ELND005 is NO LONGER the lead drug.
And u don't seem to understand anything? Tt401 is the companies lead drug
About Transition
Transition is a biopharmaceutical development company, advancing novel therapeutics for CNS and metabolic disease indications. The Company's wholly-owned subsidiary, Transition Therapeutics Ireland Limited is developing CNS drug candidate ELND005 for the treatment of Alzheimer's disease and Down syndrome. Transition's lead metabolic drug candidate is TT401 (LY2944876) for the treatment of type 2 diabetes and accompanying obesity. The Company's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.